Central China's Pioneer in Clinical Innovation and Precision Medicine
Zhongnan Hospital (中南医院) is affiliated with Wuhan University Medical School and located in the Wuchang District of Wuhan, overlooking East Lake. While Tongji Hospital and Union Hospital command higher overall rankings based on surgical volume, Zhongnan has built a distinct identity as the region's innovation hub — the first hospital in Central China to introduce PD-1 and PD-L1 checkpoint inhibitors into clinical practice, to offer comprehensive NGS molecular tumour profiling as a routine diagnostic tool, and to adopt combination immunotherapy protocols at scale.
For patients with difficult-to-treat cancers who have exhausted standard options, or who specifically want access to the latest investigational agents within China's cancer treatment ecosystem, Zhongnan's combination of trial depth and precision medicine infrastructure makes it the relevant choice. The hospital is also a national referral centre for dermatology and ophthalmology. Learn more about cancer treatment access in China.
With over 2,500 inpatient beds and 100+ active clinical trials, Zhongnan functions both as a high-quality community cancer centre for standard treatment and as a gateway to investigational therapies not yet widely available.
"For patients who need access to the newest drugs and trial options — not just the most established hospitals — Zhongnan is where innovation happens fastest in Central China."
Three reasons international patients choose Zhongnan Hospital Wuhan
Consistent track record as the first hospital in Central China to open enrollment in major oncology trials. 100+ active trials spanning immunotherapy combinations, targeted agents, and novel treatment sequences. China Care assesses your eligibility against Zhongnan's active trial portfolio before you travel.
Comprehensive NGS analysis for solid tumour molecular profiling identifies actionable mutations including EGFR, ALK, ROS1, KRAS, HER2, MSI status, and TMB. Results guide matching to targeted therapy, immunotherapy eligibility assessment, and clinical trial suitability. Particularly valuable for patients who have already received standard chemotherapy lines.
Located in the Wuchang district of Wuhan with direct access from Wuhan Tianhe Airport. A practical choice for a Central China oncology second opinion without longer wait times typical at Tongji or Union. China Care coordinates appointments within 3–5 business days for most oncology cases.
Specialties Available to International Patients
The departments most commonly accessed by international patients coordinated through China Care.
Comprehensive cancer treatment with NGS profiling at the diagnostic core. Immunotherapy combinations (PD-1/PD-L1, CTLA-4), targeted therapy, clinical trial access. Strong in lung, colorectal, hepatobiliary, and breast cancer.
Over 100 active trials. Rapid adoption enables earlier access to novel agents not yet in standard guidelines. Pre-travel eligibility assessment available via China Care.
First in Central China for checkpoint inhibitors. PD-1/PD-L1 monotherapy and combination protocols, CTLA-4 combinations, immune-related adverse event management.
Complex inflammatory skin conditions, autoimmune dermatoses, melanoma, squamous cell carcinoma, basal cell carcinoma, and cutaneous lymphoma. Dermoscopy, phototherapy, and biologics.
Retinal diseases, glaucoma, corneal conditions, cataract surgery, and ocular oncology. Regional referral centre for complex and rare eye conditions.
Submit your records. China Care assesses your eligibility against Zhongnan's active trial portfolio before you travel.
How to Access Treatment at Zhongnan Hospital
China Care manages the referral process for international patients at Zhongnan Hospital, including pre-travel trial eligibility assessment, proxy consultation, and on-ground coordination throughout your stay.
Send records, imaging, pathology reports, any existing NGS results, and your full treatment history. China Care prepares a bilingual case summary focused on which active trials or treatment protocols at Zhongnan may be relevant to your case.
records review · 1–2 daysChina Care attends Zhongnan Hospital in person and consults directly with the oncology team. For trial access: the team assesses your case against the active trial portfolio. For standard treatment: initial direction on NGS profiling and treatment planning.
Already in China? Skip this step — China Care arranges direct escort and interpretation for your own consultation instead.
proxy consultation · fixed fee · results same dayArmed with the initial direction from the proxy consultation, you travel to Wuhan for your in-person consultation. For trial candidates: formal enrollment screening is conducted at this stage. For standard oncology: the specialist confirms treatment plan and issues a formal cost estimate.
in-person consultation · treatment plan & cost estimate issuedChina Care coordinates your admission. For trial patients: Zhongnan's trial coordinator handles consent documentation and scheduling. For standard oncology: inpatient or outpatient treatment proceeds per the agreed plan.
All fees paid directly to the hospital in RMB.
RMB direct to hospital · China Care on-ground supportDischarge documentation provided in English. For trial participants: some follow-up visits may be possible via telemedicine, reducing the need to remain in Wuhan for the full trial period. China Care coordinates return visit logistics.
bilingual documentation · remote follow-up options